Table 2.
Proportion of patients on treatment at reported follow-up times (in months) in all study arms
| References | Indication | Line | Proportion on treatment at × months
|
||||
|---|---|---|---|---|---|---|---|
| 6 | 12 | 24 | 36 | 60 | |||
| Real-world studies identified in systematic review | |||||||
| Khalil and Tahami,34 2012 | RA | 1st | 76% | ||||
| Dalén et al,33 2016 | Mix | 1st | 76% | 58% | 46% | 40% | |
| Hirano et al,40 2015 | RA | Mix | 79% | 77% | |||
| Sato et al,20 2015 | RA | Mix | 90% | ||||
| Aaltonen et al,38 2016 | RA | Mix | 80% | ||||
| Saevarsdottir et al,35 2014 | RA | 1st | 81% | 67% | 63% | 60% | |
| PsA | 1st | 85% | 73% | 63% | 61% | ||
| AS | 1st | 85% | 80% | 68% | 64% | ||
| SpA | 1st | 81% | 75% | 67% | 67% | ||
| RA | 2nd | 77% | 63% | 56% | 54% | ||
| PsA | 2nd | 77% | 62% | 57% | 53% | ||
| AS | 2nd | 80% | 70% | 63% | 60% | ||
| SpA | 2nd | 78% | 62% | 54% | 52% | ||
| RA | 3rd+ | 65% | 47% | 40% | 32% | ||
| PsA | 3rd+ | 72% | 54% | 45% | 45% | ||
| AS | 3rd+ | 71% | 52% | 47% | 47% | ||
| SpA | 3rd+ | 63% | 60% | 54% | 60% | ||
| Favalli et al,36 2016 | RA | 1st | 57% | ||||
| RA | 2nd | 61% | |||||
| Hayashi et al,43 2016 | RA | Mix | 72% | ||||
| Manara et al,37 2016 | RA | 1st | 49% | ||||
| RA | 2nd | 53% | |||||
| PsA | 1st | 66% | |||||
| PsA | 2nd | 54% | |||||
| AS | 1st | 57% | |||||
| AS | 2nd | 76% | |||||
| Mourão et al,41 2016 | RA | 1st | 75% | ||||
| Rotar and Tomšič,39 2016 | RA | Mix | 82% | 65% | 56% | ||
| PsA | Mix | 83% | 75% | 57% | |||
| AS | Mix | 91% | 83% | 73% | |||
| Santo et al,42 2016 | Axial SpA | Mix | 75% | ||||
| RA | Mix | 63% | |||||
| PsA | Mix | 64% | |||||
| Randomized controlled clinical trials with five years follow-up data | |||||||
| Keystone et al,13 2016, GO-FORWARD study on golimumab | RA | 1st | 71% | ||||
| Smolen et al,44 2015, GO-AFTER study on golimumab | RA | 2nd | 40% | ||||
| Emery et al,45 2016, GO-BEFORE study on golimumab | RA | 1st | 66% | ||||
| Klareskog et al,46 2011, study on etanercept | RA | 1st | 56% | ||||
| Keystone et al,48 2014, RAPID 1 study on certolizumab pegol | RA | 1st | 55% | ||||
| Keystone et al,47 2011, DE019 study on adalimumab | RA | 1st | 55% | ||||
| Deodhar et al,14 2015, GO-RAISE study on golimumab | AS | 1st | 72% | ||||
| Sieper et al,49 2012, ATLAS study on adalimumab | AS | 1st | 65% | ||||
| Kavanaugh et al,15 2014, GO-REVEAL study on golimumab | PsA | 1st | 69% | ||||
Abbreviations: AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; Axial SpA, axial spondyloarthritis.